Divisadero Street Capital Management LP Cuts Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Divisadero Street Capital Management LP lowered its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 55.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 150,772 shares of the company's stock after selling 190,367 shares during the quarter. Establishment Labs accounts for 0.8% of Divisadero Street Capital Management LP's investment portfolio, making the stock its 27th largest holding. Divisadero Street Capital Management LP owned 0.54% of Establishment Labs worth $6,946,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Establishment Labs during the 4th quarter valued at approximately $27,000. R Squared Ltd purchased a new position in Establishment Labs in the 4th quarter valued at approximately $36,000. Federated Hermes Inc. raised its holdings in Establishment Labs by 3.0% during the fourth quarter. Federated Hermes Inc. now owns 32,720 shares of the company's stock worth $1,507,000 after purchasing an additional 953 shares during the last quarter. Swiss National Bank raised its holdings in Establishment Labs by 2.7% during the fourth quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in Establishment Labs by 32.3% during the fourth quarter. Handelsbanken Fonder AB now owns 8,200 shares of the company's stock worth $378,000 after purchasing an additional 2,000 shares in the last quarter. Hedge funds and other institutional investors own 72.91% of the company's stock.

Analyst Upgrades and Downgrades

ESTA has been the subject of a number of research analyst reports. Needham & Company LLC initiated coverage on Establishment Labs in a research report on Monday, April 14th. They issued a "hold" rating for the company. Stephens reissued an "overweight" rating and issued a $52.00 price objective on shares of Establishment Labs in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $57.40.

Establishment Labs Price Performance

Shares of ESTA traded up $0.74 during trading hours on Monday, reaching $34.66. 177,327 shares of the company traded hands, compared to its average volume of 465,772. The stock has a market capitalization of $999.74 million, a PE ratio of -13.45 and a beta of 0.73. The stock has a fifty day simple moving average of $34.83 and a 200 day simple moving average of $38.48. Establishment Labs Holdings Inc. has a fifty-two week low of $26.56 and a fifty-two week high of $60.12. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.13. The company had revenue of $41.38 million for the quarter, compared to analysts' expectations of $41.15 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period last year, the company earned ($0.58) EPS. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 EPS for the current fiscal year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.